Benefit of Virtual Reality Headset Use on Apathy in Older Adults With Major Neurocognitive Disorders

Last updated: September 18, 2023
Sponsor: RIVAGES
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Treatment

Casque Lumeen

Clinical Study ID

NCT06047522
2021-A02814-37
  • Ages 65-110
  • All Genders

Study Summary

The goal of this clinical trial is to verify that virtual reality is tolerably compatible with apathetic pathologies in patients and residents with major neurocognitive disorders. The main questions it aims to answer are:

  • Does virtual reality have an impact on symptoms of apathy in the elderly?

  • Is virtual reality well tolerated by the elderly? Participants will benefit from a 3-session virtual reality headset program with a healthcare professional. They will have one session per week for 3 weeks. They will be observed by another professional, who will complete observation grids on apathy, engagement in activity and tolerance of the virtual reality headset.

There is not a comparison group: Researchers will compare the scores before and after the intervention: the participant will be his own control.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Persons over 65 years of age
  • Persons living in nursing homes or hospitalized in long-term care
  • Persons with correct vision or vision corrected by glasses
  • People with no hearing problems, or with hearing loss corrected by a hearing aid
  • Person with a major neurocognitive disorder
  • Person with a Mini Mental State Examination (MMSE) cognitive score <26
  • Individuals with documented apathy

Exclusion

Exclusion Criteria:

  • Person with a history of epilepsy
  • Persons wearing a pacemaker
  • Person with open wounds of the face or skull
  • Disabling headache or neck pain
  • Person at the immediate end of life or in active palliative care
  • Person with a contagious disease
  • People who are bedridden or unable to get into a wheelchair
  • Persons with severe neurological impairment
  • Person with severe behavioral disorders endangering self or staff
  • Persons unable to give oral consent

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Casque Lumeen
Phase:
Study Start date:
January 03, 2023
Estimated Completion Date:
January 03, 2024

Study Description

This study is a multicenter interventional exploratory study in two nursing homes and a geriatric long-term care service. Thirty patients will be included. They will be recruited from residents of the long-term care departments of two hospitals, and 4 nursing homes.

A pre- and post-intervention comparison will be made by assessing apathy using the apathy inventory and the neuropsychiatric inventory in the care team version. A comparison of participants' engagement will be carried out through ecological observation of the interventions. This will be objectivized by the Caregiver Interaction Behavior Scale (ECPAI) before the immersion program, and during the first and third virtual reality sessions. An ECPAI scale taken during a conventional animation prior to the program will establish a baseline state for the participant.

The main goal is to verify that virtual reality is tolerably compatible with apathetic pathologies in patients and residents with major neurocognitive disorders.

Connect with a study center

  • Maison de retraite la Passerelle

    Larajasse, Rhône 69590
    France

    Active - Recruiting

  • Maison de retraite l'arc en ciel

    Saint-Martin-en-Haut, Rhône 69850
    France

    Active - Recruiting

  • USLD Arcadie - CHU Rouen

    Mont-Saint-Aignan, Seine Maritime 76130
    France

    Active - Recruiting

  • Hôpital Charles Foix

    Ivry-sur-Seine, Val De Marne 94200
    France

    Active - Recruiting

  • EHPAD d'Enghien

    Enghien-les-Bains, Val d'Oise 95880
    France

    Site Not Available

  • EHPAD Louis Grassi

    Presles, Val d'Oise 95590
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.